IGF1 and pulmonary arterial hypertension: It may contribute to PAH pathogenesis by modulating IGF bioavailability, influencing PASMC proliferation and migration, and potentially linking metabolic dysregulation to vascular remodeling. and It requires further validation before clinical translation